Immunotherapy as a partner for HER2-directed therapies.

Area of Science:

• Oncology
• Immunotherapy
• Cancer Therapeutics

Background:

• HER2-targeted therapies positively modulate the tumor microenvironment and immune response.
• Despite improvements in HER2-overexpressing malignancies, novel treatment strategies are needed.

Purpose of the Study:

• To review the immunomodulatory effects of approved HER2-targeted therapies.
• To discuss preclinical and initial clinical data on combining HER2-targeted agents with immunomodulatory drugs, checkpoint inhibitors, and cancer vaccines in breast cancer.

Main Methods:

• Literature review of approved HER2-targeted therapies.
• Analysis of preclinical data on combination therapies.
• Summary of initial clinical studies involving HER2-targeted agents with immunotherapy.

Main Results:

• Preclinical data suggest synergistic effects between HER2-targeted therapy and immunotherapy (checkpoint inhibitors, cancer vaccines).
• Initial trials of HER2-targeted therapy with PD-1/PD-L1 blockade yielded negative results, but responses were observed in PD-L1+ patients.
• Trastuzumab combined with HER2-targeted cancer vaccination showed benefits in triple-negative breast cancer.

Conclusions:

• HER2-targeted therapies possess immunomodulatory properties.
• Combinations with immunotherapies hold potential, especially in specific patient subgroups.
• Further clinical trials are essential to validate the efficacy of these combined treatment approaches.